PATENT CLAIM ANALYSIS

Application Number: 16031399
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["544", "269000"]

Abstract:
The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.

Claim (Index 20):
The method of  claim 17  wherein the TRPC5 mediated disorder is borderline personality disorder or depressive disorders, major depression, major depressive disorder, psychiatric depression, dysthymia, postpartum depression, bipolar disorders, post-traumatic stress disorder, panic disorder, agoraphobia, social phobias, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, separation anxiety, Alzheimer's disease, amnesia, aphasia, brain injury, brain tumor, chronic fatigue syndrome, Creutzfeldt-Jakob disease, dissociative amnesia, fugue amnesia, Huntington's disease, learning disorders, sleeping disorders, multiple personality disorder, pain, post-traumatic stress disorder, schizophrenia, sports injuries, stroke, Wernicke-Korsakoff syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.09677
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14822018', '14822135', '14822232', '14822022', '14822079']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7577696606435818
- 35 USC 102 Novelty (BERT): 0.5176331397570956
- Combined Prediction Score: 0.7337560085549332
- Mean Citation Score: 260.703756
- Max Citation Score: 270.3011
- Similarity Product: 171.1324364155173

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test